# FINAL FISCAL NOTE

**Drafting Number:** LLS 19-0588  
**Prime Sponsors:** Rep. Jaquez Lewis  
Sen. Winter  
**Date:** July 9, 2019  
**Bill Status:** Signed into Law  
**Fiscal Analyst:** Erin Reynolds | 303-866-4146  
Erin.Reynolds@state.co.us

## Bill Topic:
PRESCRIPTION DRUG COST EDUCATION

### Summary of Fiscal Impact:
- state Revenue
- state Expenditure (minimal)
- state Transfer
- TABOR Refund
- Local Government
- Statutory Public Entity

This bill requires prescription drug manufacturers to provide wholesale acquisition drug costs and generic drug equivalents to prescribers when providing drug-related information. It will minimally increase state workload in FY 2019-20.

### Appropriation Summary:
No appropriation is required.

### Fiscal Note Status:
The fiscal note reflects the enacted bill.

## Summary of Legislation

This bill requires a prescription drug manufacturer to provide the wholesale acquisition cost of a prescription drug when providing information concerning the drug to the prescriber, as well as the names of at least three generic prescription drugs from the same therapeutic class.

## State Expenditures

In FY 2019-20, the State Board of Pharmacy in the Department of Regulatory Agencies will have a minimal workload increase to perform rulemaking to implement the bill. This can be accomplished within existing appropriations.

## Effective Date

The bill was signed into law by the Governor on May 16, 2019. Section 1 of the bill takes effect August 2, 2019, assuming no referendum petition is filed. Section 2 of the bill takes effect on October 1, 2019.
### State and Local Government Contacts

<table>
<thead>
<tr>
<th>Counties</th>
<th>Higher Education</th>
<th>Law</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public Health and Environment</td>
<td>Regulatory Agencies</td>
<td></td>
</tr>
</tbody>
</table>